EUROAPI Enters Five-Year CDMO Agreement with Priothera

• EUROAPI and Priothera ink 5-year deal for oncology molecule production.

• Agreement focuses on developing and manufacturing mocravimod at EUROAPI’s Budapest site.

EUROAPI has announced a five-year development and manufacturing agreement with Priothera, a biotechnology company focused on treatments for hematological malignancies and CAR-T cell therapies. This collaboration aims to develop and industrialize the manufacturing process of mocravimod, an innovative oncology molecule, through EUROAPI’s Contract Development and Manufacturing Organization (CDMO) activity.

The project will be conducted at EUROAPI’s Budapest site, which serves as its center of excellence for complex chemistry. Cécile Maupas, Chief CDMO Officer of EUROAPI, stated, “Oncology is a major segment for EUROAPI’s CDMO business. Signing this development and manufacturing agreement with Priothera demonstrates our ability to adapt to state-of-the-art innovation and quality requirements.”

Florent Gros, Co-Founder and Chief Executive Officer of Priothera, commented, “Having EUROAPI as a commercial manufacturing partner brings substantial value to Priothera, which is accelerating its late development of mocravimod in a global phase 3 clinical study with a view to worldwide drug registration and commercialization by 2027.”

Mocravimod is a S1P1 receptor modulator designed as an adjunctive and maintenance treatment for blood cancers. It aims to reduce relapses and increase patient survival rates. Currently, mocravimod is being developed in a global phase 3 trial, enrolling approximately 250 adult Acute Myeloid Leukemia patients across the US, Europe, Asia, and Latin America. The molecule has received Orphan Drug designation from both the EMA and the US FDA.